	US 12,264,366 B2
	Genome-based methods for reducing cardiovascular risk
Amy Damask, Tarrytown, NY (US); Charles Paulding, Tarrytown, NY (US); Aris Baras, Tarrytown, NY (US); and Goncalo Abecasis, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on May 16, 2020, as Appl. No. 16/876,030.
Claims priority of provisional application 62/933,181, filed on Nov. 8, 2019.
Claims priority of provisional application 62/849,670, filed on May 17, 2019.
Prior Publication US 2021/0002724 A1, Jan. 7, 2021
Int. Cl. C12Q 1/6883 (2018.01); A61K 39/00 (2006.01); C07K 16/40 (2006.01); G16B 20/00 (2019.01); G16B 40/20 (2019.01)

CPC C12Q 1/6883 (2013.01) [C07K 16/40 (2013.01); G16B 20/00 (2019.02); G16B 40/20 (2019.02); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01)]

7 Claims

1. A method of treating a patient who has received or is currently receiving an intensive statin therapy treatment, and who has a high genetic risk of recurrent major adverse cardiovascular event (MACE) despite intensive statin therapy, comprising administering a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor to the patient, wherein the patient:

does not have elevated levels of lipoprotein(a) (LPA or LP (a)) or LDL-C; and

has a coronary artery disease polygenic risk score (CAD-PRS) greater than the 90^thpercentile determined from a reference population, wherein the CAD-PRS comprises a weighted sum of a plurality of genetic variants associated with coronary artery disease;

wherein the patient receiving the PCSK9 inhibitor demonstrates reduced absolute and relative risk of developing recurring MACE compared to a patient with the same CAD-PRS receiving placebo treatment.